Información del artículo
Resumen
Se presentaron alrededor de 1.000 comunicaciones sobre enfermedad inflamatoria intestinal en la DDW 2008. Nuestra intención en este trabajo es resumir lo más importante presentado con respecto a métodos diagnósticos, tabaco, cáncer, en relación con las EII. La resonancia megnética parece que está adquiriendo cada vez más importancia en el diagnóstico de la enfermedad de Crohn. Siguen acumulándose datos que demuestran que el tabaco influye negativamente en la evolución de la enfermedad de Crohn también cuando es tratada en unidades muy especializadas, incluso con dosis moderadas. Al incluir los estudios de base poblacional, el cáncer colorrectal no es tan frecuente como señalan los estudios procedentes de centros de referencia. Sin embargo, su incidencia sigue justificando las medidas de vigilancia, aunque cada vez más datos sugieren que un buen control de la inflamación es clave para disminuir la incidencia del cáncer.
Palabras clave:
Enfermedad de Crohn
Colitis ulcerosa
Colorrectal cancer
Magnetic resonance
Tabaco
Clostridium difficile
Abstract
At DDW 2008 around 1000 abstracts on inflammatory bowel disease were presented. Our goal in this report is to sumaries the most important new data on diagnosis, smoking and cancer related to IBD. MRI is emerging as a basic diagnostic tool in Crohn's disease. New data are accumulating demonstrating that smoking has a negative impacto on natural history of CD even when treated in very specialized units, and with moderate tobacco use. When population-based studies are considered, colorrectal cancer is not so a frequent complication as has been reported in referente centres. However, its incidente does fully justify surveillance, although more and more data show that the key point to disminsh the incidence of cancer is a good control of inflammation.
Key words:
Crohn's disease
Ulcerative colitis
Colorrectal cancer
MRI
Smoking
Clostridium difficile
El Texto completo está disponible en PDF
Bibliografía
[1.]
P. Seksik, I. Non-Larmurier, L. Beaugerie, J. Cosnes.
is a ligth tobacco consumption deletereous in Crohn's disease?.
Gastroenterology, 124 (2008), pp. A-4
[2.]
G. Parkes, T. Greenhalgh, M. Griffin, R. Dent.
Effect on smoking qui trate of telling patients their lung age: the step2quit randomised controlled trial.
BMJ, 336 (2008), pp. 598-600
[3.]
D. Lissner, W. Reinisch, P. Papay, E. Ho, C. Gratzer, C. Dejaco, et al.
Passive smoking during childhood increases the risk for intestinal surgery in patients with Crohn's Disease.
Gastroenterology, 124 (2008), pp. M1158
[4.]
L. Costes, J.F. Colombel, J.Y. Mary, B. Duclos, M. Veyrac, J.L. Dupas, et al.
Long term follow-up of a cohort of steroid-dependent Crohn's disease patients included in a randomized trial evaluating short term infliximab combined with azathioprine.
Gastroenterology, 124 (2008), pp. A134
[5.]
L.V. McFarland.
Update on the changing epidemiology of Clostridium difficile-associated disease.
Nat Clin Pract Gastroenterol Hepatol, 5 (2008), pp. 40-48
[6.]
E.M. Clayton, M.C. Rea, F. Shanahan, E.M. Quigley, B. Kiely, P. Ross, et al.
The vexed relationship between Clostridium difficile and inflammatory bowel disease (IBD): a prospective assesment of carriage in an outpatient setting in patients in remission.
Gastroenterology, 124 (2008), pp. A14
[7.]
F. Pascarella, E. Miele, M. Martinelli, E. Roscetto, M.M.A. Del Pezzo, F. Rossano, et al.
Impact of Clostridium difficile infection on pediatric inflammatory bowel disease.
Gastroenterology, 124 (2008), pp. A14
[8.]
M. Hu, S. Maroo, J. Cloud, S. Tummala, K. Katchar, V. Dreisbach, et al.
Failure of metronidazole therapy for C. difficile-associated disease. Risk factors and historical trenes.
Gastroenterology, 124 (2008), pp. A670
[9.]
M.A. Pastrana Ledesma, J. De Miguel Criado, I. Pérez González, L. Ramos Gonzáles.
Nuevas técnicas de imagen: US, TC, RM enterografía y PET en el diagnóstico y seguimiento de la EICI.
Enfermedad Inflamatoria al Día, 3 (2008), pp. 141-153
[10.]
Z. Levi, R. Krongard, R. Hazazi, O. Benjaminov, J. Meyerovitch, O. Bar Tal, et al.
Crohn's disease, surgery and male sex are risk factors for radiation exposure in patients with inflammatory bowel disease.
Gastroenterology, 124 (2008), pp. A20
[11.]
A.N. Desmond, K.N. O’Regan, C. Curran, S. McWilliams, M.M. Maher, F. Shanahan.
Crohn's disease: factors associated with exposure to high levels of diagnostic radiation.
Gastroenterology, 124 (2008), pp. A20
[12.]
J. Panés, J. Rímola, S. Rodríguez, O. García-Bosch, M. Pellisé, E. Ricart, et al.
Magnetic resonante is a reliable technique for assesment of diesease activity and severity in colonic Crohn disease.
Gastroenterology, 124 (2008), pp. A20
[13.]
R. Botwell.
A colouful future for MRE.
Nature, 453 (2008), pp. 993-994
[14.]
J. Adler, S.D. Swanson, A.D. Polydorides, B.J. McKenna, H.K. Hussain, P.D. Higgins, et al.
Magnitization transfer MRI quantitativeky detects intestinal fibrosis in exvivo human intestinal tissue in Crohn's disease.
Gastroenterology, 124 (2008), pp. A21
[15.]
J.P. Gisbert, F. Gomollón, J. Maté, J.M. Pajares.
The role o fantineutrophil cytoplasmic antibodies (ANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA) in inflammatory bowel disease.
Gastroenterol Hepatol, 26 (2003), pp. 312-324
[16.]
F. Rieder, A. Wolf, S. Schleder, A. Dirmeier, U. Strauch, F. Obermeier, et al.
The novel anti-glycan antibodies Anti-L and Anti-C in conjuction with ALCA, ACCA, Gasca, and AMCA predict early development of fistulae, stenosis, and surgery in patients with Crohn's disease: a prospective analysis.
Gastroenterology, 124 (2008), pp. A53
[17.]
C. Seow, J.M. Stempak, W. Xu, H. Lan, A.M. Griffiths, G. Greenberg, et al.
Two novel polysaccharide antibodies (anti-laminarin and anti-chitin) predict an aggressive Crohn's phenotype and improve differentiation between Crohn's disease and ulcerative colitis.
Gastroenterology, 124 (2008), pp. A53
[18.]
F. Rieder, S. Schleder, A. Wolf, A. Dirmeier, U. Strauch, F. Obermeier, et al.
Specific levels and combinations of the anti-glycan antibodies anti-L, anti-C, ALCA, ACCC, Gasca and AMCA contribute to diagnosis and differential diagnosis of patients with Crohn's disease and are associated with complicated disease and surgery.
Gastroenterology, 124 (2008), pp. A53
[19.]
J.P. Gisbert, F. Bermejo, J.I. Pérez-Calle, C. Taxonera, I. Vra, Y. González-Lama, et al.
Faecal calprotecti's utility in the prediction of inflammatory bowel disease (IBD) relapses.
Gastroenterology, 124 (2008), pp. A196
[20.]
J.P. Gisbert, A.G. McNicholl.
The diagnostic accuracy of faecal calprotectin in inflammatory bowel disease (IBD): a systematic review.
Gastroenterology, 124 (2008), pp. A196
[21.]
A. Castells, M. Marzo, B. Bellas, F.J. Amador, A. Lanas, J.J. Mascort, et al.
Clinical guidelines for the prevention of colorrectal cancer.
Gastroenterol Hepatol, 27 (2004), pp. 573-634
[22.]
J. Eaden, K.R. Abrams, J.F. Mayberry.
The risk of colorrectal cancer in ulcerative colitis: a meta-analysis.
Gut, 48 (2001), pp. 526-535
[23.]
M.W. Lutgens, G.J. Van der Heijden, F.P. Vleggaar, R. Oldenburg.
A comprehensive meta-analysis of the risk of colorrectal cancer in Ulcerative Colitis and Crohn's disease.
Gastroenterology, 124 (2008), pp. A33
[24.]
M. Garrity-Park, E.V. Loftus, W.J. Sandborn, S.C. Bryant, T.C. Smyrk.
HLA class II genotype predicts increased risk for ulcerative colitis associated cancer and correlatos with methylation of the MHC class II transactivator (CIITA) gene.
Gastroenterology, 124 (2008), pp. A34
[25.]
M.W. Lutgens, B. Oldenburg, P.D. Siersema, F.P. Vleggar.
Colonoscopic surveillance in inflammatory bowel disease improves survival alter colorrectal cancer diagnosis.
Gastroenterology, 124 (2008), pp. A34
[26.]
J.F. Marion, J.D. Waye, D. Present, Y. Israel, C.A. Bodian, N. Harpaz, et al.
Follow-up chromoendoscopy continues to be superior to standard colonoscopic surveillance for managing dysplasia in patients with IBD. A long-term, prospective, endoscopic trial.
Gastroenterology, 124 (2008), pp. A34
[27.]
B.K. Popivanova, K. Kitamura, Y. Wu, T. Kondo, T. Kagaya, S. Kaneko, et al.
Blocking TNFa in mice reduces colorrectal carcinogenesis associated with chronic colitis.
J Clin Invest, 118 (2008), pp. 560-570
[28.]
J.A.P. Wilson.
Tumor necrosispov factor a and colitis-associated colon cancer.
N Engl J Med, 358 (2008), pp. 2733-2735
[29.]
H. Singh, A. Demers, Z. Nugent, S. Mahmud, E.V. Klewer, C.N. Bernstein.
Risk of cervical abnormalities in women with IBD: a population-based study.
Gastroenterology, 124 (2008), pp. A143
[30.]
T.E. Lyles, R.A. Oster, A. Gutiérrez.
Prevalence of abnormal PAP smears in patients with inflammatory bowel disease on immune modulator therapy.
Gastroenterology, 124 (2008), pp. A143
[31.]
C.W. Lees, J. Critxhey, N.M. Chee, A.G. Shand, I.D. Arnott, J. Satsangi.
Cervical dysplasia and inflammatory bowel disease: no effect of disease status or immunosuppressants on analysis of 2199 smear records.
Gastroenterology, 124 (2008), pp. A143
[32.]
C.W. Lees, C.L. Noble, L. Diehl, J. Satsangi.
Expression analysis of all genes implicated in susceptibility to Crohn's disease from genome-wide association studies.
Gastroenterology, 124 (2008), pp. A41
[33.]
A. Franke, T.C. Balschum, J. Hedderich, T. Hemming, S. May, T.T. Lu, et al.
Replication of signals from recent genome wide association studies in Crohn disease identifies new disease genes for ulcerative colitis in a large German patient panel.
Gastroenterology, 124 (2008), pp. A41
[34.]
J.H. Cho.
The genetics and immunopathogenesis of inflammatory bowel disease.
Nat Rev Immunol, 8 (2008), pp. 458-466
[35.]
A. Franke, T. Balschum, T.H. Karlsen, J. Hedderich, S. May, T. Lu, et al.
Replication of signals from recent studies of Crohn's disease identifies previously unknon disease loci for ulcerative colitis.
Nat Genet, 40 (2008), pp. 710-712
[36.]
The Wellcome Trust Case Control Consortium.
Genome-wide association study of 14.000 cases of seven common diseases and 3.500 shared controls.
Nature, 447 (2007), pp. 661-678
[37.]
C.G. Mathew.
New links to the patogenesis of Crohn disease provided by genome association scans.
Nat Rev Genet, 9 (2008), pp. 9-14
[38.]
I. Arijs, L.V. Van Lommel, K. Van Steen, et al.
Mucosal gene signaturas to predict response to infliximab in patients with inflammatory bowel disease.
Gastroenterology, 124 (2008), pp. A117
[39.]
P. Von Stein, R. Lofberg, N.V. Kuznetsov, A.W. Gielen, J.O. Persson, R. Sundberg, et al.
Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome.
Gastroenterology, 134 (2008), pp. 1869-1881
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
